- Home
- BRT vs AQST Comparison
BRT vs AQST Comparison
Compare BRT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | AQST |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.9M | 809.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BRT | AQST |
|---|---|---|
| Price | $14.95 | $6.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $19.75 | $10.00 |
| AVG Volume (30 Days) | 99.0K | ★ 2.5M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 6.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,001,000.00 | $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | $52.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.30 | N/A |
| 52 Week Low | $14.00 | $2.12 |
| 52 Week High | $19.30 | $7.55 |
Technical Indicators
Market Signals| Indicator | BRT | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 54.05 |
| Support Level | $14.45 | $5.99 |
| Resistance Level | $15.14 | $6.44 |
| Average True Range (ATR) | 0.30 | 0.31 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 87.16 | 61.19 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.